Aclarion Inc. (Nasdaq: ACON, ACONW) has secured nearly $20 million in gross proceeds since Jan. 1, 2025, which fully funds its pivotal CLARITY trial. The trial is designed to demonstrate the clinical and economic value of Nociscan in spine surgery. Ryan Bond, chief strategy officer of Broomfield-based Aclarion, said, “This milestone ensures we reach the…
This Article Is Locked, But Not Out of Reach
Jeffco BdB delivers smart insights on local businesses. Get a free account to unlock rankings, trends, and alerts tailored to you.
Curious how it works? Watch the Quickstart
Want everything unlocked? See Paid Options
Already a member? Log in here